Pertinax Pharma Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 1

Employees
  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $447K

  • Investors
  • 6

Pertinax Pharma General Information

Description

Developer of antimicrobial technologies intended to be used in medical devices. The company's products can be incorporated into a wide range of medical device material substrates, including polymers and coatings, enabling healthcare professionals to offer longer antimicrobial and antifungal protection.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Medical Supplies
Primary Office
  • Research and Enterprise Development University Of Bristol
  • 2nd Floor, Augustines Courtyard
  • Bristol BS1 5DS
  • England, United Kingdom

Pertinax Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pertinax Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC 21-Mar-2019 $447K 00.000 00.000 Completed Generating Revenue
7. Grant 16-Jan-2019 000.00 00.00 Completed Generating Revenue
6. Early Stage VC 11-Oct-2018 00.000 00.00 00.000 Completed Generating Revenue
5. Seed Round 15-Mar-2017 00000 00.000 00.000 Completed Startup
4. Grant 01-Jun-2016 000.00 00000 Completed Startup
3. Early Stage VC 11-Apr-2016 00000 00000 00.000 Completed Startup
2. Grant 11-Mar-2016 $768K Completed Startup
1. Accelerator/Incubator 01-Mar-2015 Completed Startup
To view Pertinax Pharma’s complete valuation and funding history, request access »

Pertinax Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 39,000 $0.000132 $21.1 $21.1 1x $21.1 11.66%
A Ordinary 36,958 $0.000132 $15.14 $15.14 1x $15.14 11.05%
To view Pertinax Pharma’s complete cap table history, request access »

Pertinax Pharma Executive Team (3)

Name Title Board Seat Contact Info
Michele Barbour Ph.D Founder & Chief Executive Officer
You’re viewing 1 of 3 executive team members. Get the full list »

Pertinax Pharma Board Members (4)

Name Representing Role Since
Isabel Dodd Ph.D Mercia Asset Management Board Member 000 0000
You’re viewing 1 of 4 board members. Get the full list »

Pertinax Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pertinax Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovation 4 Growth Corporation 000 0000 000000 0
Mercia Asset Management Venture Capital Minority 000 0000 000000 0
Perivoli Innovations Trust Venture Capital Minority 000 0000 000000 0
The Armourers and Brasiers Not-For-Profit Venture Capital 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »